Clinical Trial Update: A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating tucidinostat in combination with sintilimab and bevacizumab for MSS/pMMR colorectal cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Sintilimab (sintilimab)
• Tucidinostat (tucidinostat)

Snippet

Sponsor: Chipscreen Biosciences, Ltd. | Conditions: Colorectal Cancer | Phase 3 | Status: RECRUITING